Biology Open (Dec 2017)

Bax-inhibiting peptide attenuates bleomycin-induced lung injury in mice

  • Kunihiro Suzuki,
  • Toyoshi Yanagihara,
  • Tetsuya Yokoyama,
  • Takashige Maeyama,
  • Saiko Ogata-Suetsugu,
  • Masako Arimura-Omori,
  • Hironori Mikumo,
  • Naoki Hamada,
  • Eiji Harada,
  • Kazuyoshi Kuwano,
  • Taishi Harada,
  • Yoichi Nakanishi

DOI
https://doi.org/10.1242/bio.026005
Journal volume & issue
Vol. 6, no. 12
pp. 1869 – 1875

Abstract

Read online

Bax is a pro-apoptotic member of the Bcl-2 family of proteins, and plays a central role in mitochondria-dependent apoptosis. Several lines of evidence have implied that Bax is involved in both epithelial apoptosis and fibroblast proliferation in idiopathic pulmonary fibrosis; however, the mechanisms remain unknown. Bax-inhibiting peptide V5 (BIP-V5) exhibits membrane permeability and inhibits the activation of Bax. The purpose of this study was to investigate whether the control of Bax activity by BIP-V5 reduces the degree of bleomycin-induced lung injury. C57BL/6J mice were administered bleomycin and BIP-V5 intratracheally on day 0. Bronchoalveolar lavage fluid and lung tissue were obtained on day 7. Human pulmonary alveolar epithelial cells (A549 cells) and mouse pulmonary alveolar epithelial cells (LA-4 cells) were stimulated with bleomycin to induce apoptosis. Administration of BIP-V5 improved the survival rate and degree of bleomycin-induced lung injury by suppressing Bax activation in mice. BIP-V5 treatment decreased bleomycin-induced apoptosis of alveolar epithelial cell lines (A549 cells and LA-4 cells) by suppressing Bax activation. These results indicate that administration of BIP-V5 may constitute a novel therapeutic strategy against lung injury.

Keywords